Jefferies Raises Price Target on Nektar Therapeutics (NKTR) to $15

November 7, 2016 8:58 AM EST
Get Alerts NKTR Hot Sheet
Price: $12.02 -1.88%

Rating Summary:
    11 Buy, 1 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade NKTR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies reiterated a Buy on Nektar Therapeutics (NASDAQ: NKTR), and raised the price target to $15.00 (from $14.00), following the company's 3Q earnings report. Based on the recently completed equity offering and mgt’s updated guidance, Jefferies now estimates FY16 & FY17 revenues and EPS of $170M & ($1.17) and $284 & ($0.57) vs $188M & ($1.07) and $303M & ($0.45) respectively.

Analyst David Steinberg commented, "A Q3 EPS loss of $0.32 was largely in-line with our ($0.34) estimate. A significant improvement in gross margin (75% vs 50% JEF) offset slightly lower than projected revenue (-$3M vs our estimate). Importantly, product & royalty income increased $12.8M Y/Y to $20.3M, reflecting NKTR’s growing revenue stream from Movantik and Adynovate. Looking ahead, NKTR has an abundance of key catalysts over the next 6 months."

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $12.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings, Equity Offerings

Add Your Comment